Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
The solvency position, as indicated by the presented ratios, demonstrates a generally stable trend with some notable fluctuations over the observed period. Overall, the company maintains a moderate level of debt relative to its equity, capital, and assets, with a consistent ability to cover its interest obligations. However, a discernible shift in certain metrics warrants further attention.
- Debt to Equity
- The debt to equity ratio began at 0.81 and generally decreased through October 2022, reaching a low of 0.67. It then increased to 0.83 by April 2023 before declining again to 0.63 by December 2024. The most recent periods show a slight increase, reaching 0.74 by December 2025. This suggests a fluctuating reliance on equity financing, with a recent tendency towards increased debt relative to equity.
- Debt to Capital
- The debt to capital ratio exhibits a similar pattern to debt to equity, starting at 0.45 and decreasing to 0.40 by October 2022. It remained relatively stable between 0.43 and 0.45 from December 2022 through June 2024, before decreasing to 0.39 in December 2024. The ratio then stabilized around 0.41-0.42, ending at 0.42 in December 2025. This indicates a consistent, though slightly decreasing, proportion of debt financing within the company’s capital structure.
- Debt to Assets
- The debt to assets ratio followed a comparable trend, decreasing from 0.36 to 0.32 by October 2022, then increasing to 0.37 by April 2023. It remained relatively stable around 0.35-0.37 for most of the period, with a dip to 0.32 in December 2024, before ending at 0.36 in December 2025. This suggests a consistent proportion of assets financed by debt, with minor fluctuations.
- Financial Leverage
- Financial leverage, measured as total assets to total equity, generally decreased over the period. Starting at 2.26, it declined to a low of 1.96 in December 2024. It then showed a slight increase to 2.07 by December 2025. This indicates a decreasing reliance on financial leverage, although the recent periods suggest a stabilization of this trend.
- Interest Coverage
- The interest coverage ratio demonstrates a consistent downward trend. Beginning at 16.73, it decreased steadily to 6.12 by December 2025. While the ratio remains comfortably above 1, indicating a strong ability to meet interest obligations, the declining trend warrants monitoring. The most significant decrease occurred between April 2023 and December 2023, suggesting a potential impact from changing interest rates or debt structure.
In summary, the company’s solvency ratios suggest a generally stable financial position, although the declining interest coverage ratio is a point to observe. The fluctuations in debt ratios indicate a dynamic capital structure, while the overall trend suggests a moderate and manageable level of debt.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term obligations and current maturities of long-term obligations | |||||||||||||||||||||
| Long-term obligations, excluding current maturities | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q4 2025 Calculation
Debt to equity = Total debt ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt-to-equity ratio for the analyzed period demonstrates fluctuations while generally remaining within a relatively narrow range. Initially, a decreasing trend is observed, followed by periods of stability and subsequent increases. This suggests a dynamic approach to capital structure management.
- Initial Decline (Apr 2, 2022 – Oct 1, 2022)
- The debt-to-equity ratio decreased from 0.81 to 0.67 over the first six months of the period. This indicates a reduction in relative debt levels compared to equity, potentially through debt repayment or an increase in shareholders’ equity.
- Stabilization and Increase (Oct 1, 2022 – Apr 1, 2023)
- Following the initial decline, the ratio stabilized around 0.78 before increasing to 0.83 by April 1, 2023. This suggests a renewed reliance on debt financing or a decrease in equity, potentially due to share repurchases or retained earnings allocation.
- Mid-Period Fluctuations (Apr 1, 2023 – Dec 31, 2023)
- The ratio experienced further fluctuations, decreasing to 0.75 by December 31, 2023. This period shows a moderate level of debt relative to equity, with some volatility.
- Recent Trends (Dec 31, 2023 – Jun 28, 2025)
- A notable decrease to 0.63 was observed by December 31, 2024, representing the lowest point in the analyzed period. Subsequently, the ratio increased to 0.74 by December 31, 2025. This recent increase suggests a potential shift towards increased leverage or a slower growth rate in equity compared to debt. The ratio remained relatively stable between 0.70 and 0.72 during the period from March 29, 2025 to September 27, 2025.
Overall, the debt-to-equity ratio indicates a generally conservative capital structure, with periodic adjustments likely driven by financing activities and profitability. The recent increase warrants monitoring to assess its potential impact on the company’s financial risk profile.
Debt to Capital
| Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term obligations and current maturities of long-term obligations | |||||||||||||||||||||
| Long-term obligations, excluding current maturities | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | |||||||||||||||||||||
| Total capital | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q4 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio for the analyzed period demonstrates a relatively stable pattern with minor fluctuations. Initially, a decreasing trend is observed, followed by a period of stabilization, and then a slight increase towards the end of the observed timeframe.
- Overall Trend
- The debt to capital ratio began at 0.45 in April 2022 and generally decreased to a low of 0.40 in October 2022. It then stabilized around 0.43 to 0.45 for several quarters, before increasing to 0.42 in December 2025. This suggests a generally conservative capital structure, with only moderate changes in the proportion of debt financing.
- Short-Term Fluctuations
- A noticeable decrease occurred between April 2022 and October 2022, indicating a reduction in debt relative to capital during that period. A subsequent increase in total debt during December 2022, alongside a smaller increase in total capital, led to a slight rise in the ratio. The ratio remained relatively consistent through the first half of 2023 and into 2024.
- Recent Developments
- The most recent quarters show a slight upward trend, with the ratio increasing from 0.39 in December 2024 to 0.42 in December 2025. This suggests a potential shift towards increased leverage, although the change remains modest. The increase in both total debt and total capital contributed to this change.
- Capital Structure
- Throughout the analyzed period, the debt to capital ratio remained below 0.50, indicating that, overall, the entity relies more on capital than debt for its financing. The consistent values suggest a deliberate approach to maintaining a specific capital structure.
In summary, the debt to capital ratio exhibits a pattern of initial decline, stabilization, and a recent slight increase. The overall trend suggests a reasonably stable capital structure with a moderate level of debt financing.
Debt to Assets
| Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term obligations and current maturities of long-term obligations | |||||||||||||||||||||
| Long-term obligations, excluding current maturities | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q4 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt-to-assets ratio for the analyzed period demonstrates a generally stable pattern with moderate fluctuations. Initially, the ratio decreased from 0.36 in April 2022 to 0.32 in October 2022, indicating a relative reduction in leverage. Subsequently, the ratio experienced an increase, peaking at 0.37 in April 2023, before stabilizing around 0.35 to 0.36 for the following six quarters.
A notable decrease to 0.32 occurred in December 2024, suggesting a reduction in debt relative to assets. This decrease was short-lived, as the ratio increased to 0.36 by December 2025. Overall, the ratio remained within a relatively narrow range, indicating consistent financial leverage throughout the analyzed timeframe.
- Initial Decline (Apr 2022 - Oct 2022)
- The initial decline in the debt-to-assets ratio suggests a potential strategy of reducing debt or increasing asset holdings during this period. The decrease, while not substantial, indicates a move towards a more conservative capital structure.
- Stabilization and Fluctuation (Oct 2022 - Sep 2024)
- The period between October 2022 and September 2024 shows a stabilization of the ratio around 0.35 to 0.37. This suggests a consistent approach to managing debt and assets, with minor adjustments occurring from quarter to quarter. The fluctuations within this range are likely attributable to routine business operations and financing activities.
- Recent Changes (Dec 2024 - Dec 2025)
- The decrease in the ratio to 0.32 in December 2024, followed by a rebound to 0.36 in December 2025, warrants further investigation. The temporary reduction in leverage could be due to asset sales, debt repayment, or a revaluation of assets. The subsequent increase suggests a return to previous leverage levels, potentially through new borrowing or a decrease in asset value.
In conclusion, the debt-to-assets ratio indicates a generally healthy and stable financial position. While fluctuations exist, they remain within a manageable range, and no significant or alarming trends are apparent. The recent changes at the end of the period suggest a need for continued monitoring to understand the underlying drivers of these movements.
Financial Leverage
| Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q4 2025 Calculation
Financial leverage = Total assets ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
Financial leverage, as indicated by the ratio of total assets to total shareholders’ equity, demonstrates a relatively stable pattern over the observed period. The ratio generally fluctuates between 2.0 and 2.3, suggesting a consistent reliance on financial leverage to fund assets.
- Overall Trend
- From April 2022 through June 2024, the financial leverage ratio exhibited a slight decreasing trend, moving from 2.26 to 2.05. This indicates a gradual reduction in the proportion of assets financed by equity. However, this trend reversed in the latter half of the period, with the ratio increasing to 2.07 by December 2025.
- Short-Term Fluctuations
- A minor increase in the ratio is observed between April 2022 and December 2022, followed by a decrease through June 2024. The lowest point in the observed period is reached at 1.96 in December 2024. Subsequent quarters show a modest increase, peaking at 2.07 in December 2025.
- Recent Performance
- The most recent quarters (September 2024 through December 2025) show a slight upward trend in financial leverage. While the increase is not substantial, it suggests a potential shift towards greater reliance on debt financing or a slower growth rate in equity compared to asset growth.
The consistency of the ratio suggests a deliberate approach to capital structure management. The observed fluctuations are within a narrow range, indicating a controlled level of financial risk. The recent increase warrants continued monitoring to assess whether it represents a temporary deviation or a more significant change in financial strategy.
Interest Coverage
| Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net income attributable to Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Add: Net income attributable to noncontrolling interest | |||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q4 2025 Calculation
Interest coverage
= (EBITQ4 2025
+ EBITQ3 2025
+ EBITQ2 2025
+ EBITQ1 2025)
÷ (Interest expenseQ4 2025
+ Interest expenseQ3 2025
+ Interest expenseQ2 2025
+ Interest expenseQ1 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The interest coverage ratio demonstrates a clear declining trend over the observed period, followed by a period of stabilization and a slight increase towards the end of the analysis. Initially strong, the ratio decreased significantly before showing signs of recovery.
- Overall Trend
- From April 2, 2022, to July 1, 2023, the interest coverage ratio experienced a substantial decrease, falling from 16.73 to 6.64. This indicates a weakening ability to meet interest obligations from operating earnings. Following this decline, the ratio stabilized and exhibited a modest upward trend, reaching 6.12 by December 31, 2025.
- Initial Decline (Apr 2, 2022 – Jul 1, 2023)
- The period between April 2022 and July 2023 saw a consistent reduction in the interest coverage ratio. This coincided with a decrease in Earnings Before Interest and Tax (EBIT) and a concurrent increase in interest expense. The most significant drop occurred between October 1, 2022, and July 1, 2023, suggesting a period of increased financial pressure.
- Stabilization and Recovery (Jul 1, 2023 – Dec 31, 2025)
- After reaching a low of 6.64 in July 2023, the interest coverage ratio remained relatively stable, fluctuating between approximately 5.53 and 6.25 for several quarters. The final quarters observed show a slight improvement, with the ratio increasing to 6.12 by December 31, 2025. This suggests that the company’s ability to cover its interest expense has stabilized and is showing marginal improvement.
- EBIT and Interest Expense Relationship
- The decline in the interest coverage ratio is directly attributable to the combination of decreasing EBIT and increasing interest expense. While EBIT experienced fluctuations, it generally trended downwards during the initial decline phase. Interest expense consistently increased throughout the period, exacerbating the decline in the coverage ratio. The stabilization and slight recovery in the ratio correlate with a stabilization of EBIT and a moderation in the rate of increase of interest expense.
In conclusion, the interest coverage ratio initially deteriorated significantly but has since stabilized and shown a minor recovery. Continued monitoring of both EBIT and interest expense will be crucial to assess the sustainability of this stabilization and any potential for further improvement.